Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RGNX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsREGENXBIO settles GSK royalty dispute for $10M, resolves sublicense fee claims
Filed March 20, 2026 · Period ending March 18, 2026 · ~1 min read
Key Changes
-
high
Company will pay GSK $10 million within three business days to settle dispute over allegedly underpaid sublicense fees and royalties from REGENXBIO's sublicensees under a 2009 license agreement.
Item 1.01 verify on EDGAR → -
medium
Settlement includes mutual releases of all past claims and certain future claims related to the GSK sublicense agreement, providing legal closure on historical disputes and limiting future litigation risk.
Item 1.01 verify on EDGAR → -
medium
REGENXBIO will continue using its existing methodology to calculate and pay GSK sublicense fees going forward, suggesting parties agreed to disagree on past amounts but maintain current payment structure.
Item 1.01 verify on EDGAR →
Summary
REGENXBIO has agreed to pay GSK $10 million to settle a dispute over sublicense fees and royalties. The disagreement centered on whether REGENXBIO properly calculated payments owed to GSK on amounts the company received from its own sublicensees under a 2009 license agreement. The settlement resolves all past claims and limits certain future disputes between the parties.
For investors, the $10 million payment represents a one-time cash outflow to resolve legacy accounting disagreements. More importantly, the settlement removes litigation uncertainty while preserving REGENXBIO's existing payment methodology going forward. This suggests the company successfully defended its calculation approach for future royalties even while settling past disputes.
Watch REGENXBIO's next quarterly filing for the settlement's impact on cash position and whether management provides additional context on sublicense revenue streams. The company's ability to maintain its payment methodology suggests confidence in its royalty accounting practices with other partners.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify